Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 60-64

  Barkas, Fotios ^a   Elisaf, Moses ^a   Milionis, Haralampos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Brain infarction; Cerebrovascular disease; Familial hypercholesterolemia; Inherited dyslipidemia; Ischemic stroke; Statin treatment

Indexed keywords

CLOFIBRATE; COLESTYRAMINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOTE; HUMAN; ILEUM BYPASS; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; ADOLESCENT; ADULT; AGED; CORONARY DISEASE; FEMALE; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; ODDS RATIO; STROKE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN ISCHEMIA; CORONARY DISEASE; FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; ODDS RATIO; STROKE; YOUNG ADULT;

EID: 84941006421     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.038     Document Type: Review

References (49)

1. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am. J. Epidemiol. 2004, 160(5):407-420. 10.1093/aje/kwh236.
2. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34(45):3478-3490a. 10.1093/eurheartj/eht273.
3. Goldberg A.C., Hopkins P.N., Toth P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 2011, 5(3):133-140. 10.1016/j.jacl.2011.03.001.
4. Versmissen J., Oosterveer D.M., Yazdanpanah M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008, 337:a2423. 10.1136/bmj.a2423.
5. Hutter C.M., Austin M.A., Humphries S.E. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am. J. Epidemiol. 2004, 160(5):430-435. 10.1093/aje/kwh238.
6. Vuorio A.F., Kovanen P.T. Do statins reduce the incidence of stroke in familial hypercholesterolemia?. Expert Rev. Cardiovasc. Ther. 2011, 9(3):349-353. 10.1586/erc.11.24.
7. Meschia J.F., Bushnell C., Boden-Albala B., et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2014, 45(12):3754-3832. 10.1161/STR.0000000000000046.
8. O'Donnell M.J., Xavier D., Liu L., et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010, 376(9735):112-123. 10.1016/S0140-6736(10)60834-3.
9. Prospective Studies C, Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370(9602):1829-1839. 10.1016/S0140-6736(07)61778-4.
10. Shahar E., Chambless L.E., Rosamond W.D., et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003, 34(3):623-631. 10.1161/01.STR.0000057812.51734.FF.
11. Willey J., Gonzalez-Castellon M. Cholesterol level and stroke: a complex relationship. JAMA Intern. Med. 2013, 173(19):1765-1766. 10.1001/jamainternmed.2013.10100.
12. Truelsen T., Mahonen M., Tolonen H., et al. Trends in stroke and coronary heart disease in the WHO MONICA project. Stroke 2003, 34(6):1346-1352. 10.1161/01.STR.0000069724.36173.4D.
13. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995, 346(8991-8992):1647-1653.
14. Hachinski V., Graffagnino C., Beaudry M., et al. Lipids and stroke: a paradox resolved. Arch. Neurol. 1996, 53(4):303-308.
15. Neaton J.D., Wentworth D.N., Cutler J., Stamler J., Kuller L. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. Ann. Epidemiol. 1993, 3(5):493-499.
16. Higgins J.P., Thompson S.G., Spiegelhalter D.J. A re-evaluation of random-effects meta-analysis. J. R. Stat. Soc. Ser. A Stat. Soc. 2009, 172(1):137-159. 10.1111/j.1467-985X.2008.00552.x.
17. Riley R.D., Higgins J.P., Deeks J.J. Interpretation of random effects meta-analyses. BMJ 2011, 342:d549. 10.1136/bmj.d549.
18. Kaste M., Koivisto P. Risk of brain infarction in familial hypercholesterolemia. Stroke 1988, 19(9):1097-1100.
19. Gagne C., Moorjani S., Brun D., Toussaint M., Lupien P.J. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis 1979, 34(1):13-24.
20. Mohrschladt M.F., Westendorp R.G., Gevers Leuven J.A., Smelt A.H. Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 2004, 172(2):329-335. 10.1016/j.atherosclerosis.2003.11.007.
21. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 2004, 256(6):482-490. 10.1111/j.1365-2796.2004.01405.x.
22. Bansal B.C., Sood A.K., Bansal C.B. Familial hyperlipidemia in stroke in the young. Stroke 1986, 17(6):1142-1145.
23. Kuo P.T., Toole J.F., Schaaf J.A., et al. Extracranial carotid arterial disease in patients with familial hypercholesterolemia and coronary artery disease treated with colestipol and nicotinic acid. Stroke 1987, 18(4):716-721.
24. Chambers B.R., Norris J.W. Outcome in patients with asymptomatic neck bruits. N. Engl. J. Med. 1986, 315(14):860-865. 10.1056/NEJM198610023151404.
25. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 1973, 52(7):1544-1568. 10.1172/JCI107332.
26. Patterson D., Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet 1972, 1(7747):393-399.
27. Mabuchi H., Miyamoto S., Ueda K., et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986, 61(1):1-6.
28. Heiberg A., Berg K. The inheritance of hyperlipoproteinaemia with xanthomatosis. A study of 132 kindreds. Clin. Genet. 1976, 9(2):203-233.
29. Huxley R.R., Hawkins M.H., Humphries S.E., et al. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke 2003, 34(1):22-25.
30. Masoura C., Pitsavos C., Aznaouridis K., Skoumas I., Vlachopoulos C., Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis 2011, 214(1):129-138. 10.1016/j.atherosclerosis.2010.10.008.
31. Vuorio A.F., Turtola H., Piilahti K.M., Repo P., Kanninen T., Kontula K. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler. Thromb. Vasc. Biol. 1997, 17(11):3127-3138.
32. Wiklund O., Angelin B., Olofsson S.O., et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990, 335(8702):1360-1363.
33. Frikke-Schmidt R., Nordestgaard B.G., Schnohr P., Tybjaerg-Hansen A. Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case-control and prospective study. Eur. Heart J. 2004, 25(11):943-951. 10.1016/j.ehj.2004.03.020.
34. Barkas F., Milionis H., Kostapanos M.S., Mikhailidis D.P., Elisaf M., Liberopoulos E. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr. Med. Res. Opin. 2015, 31(2):221-228. 10.1185/03007995.2014.982751.
35. Soljanlahti S., Autti T., Lauerma K., et al. Familial hypercholesterolemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis. Stroke 2005, 36(7):1572-1574. 10.1161/01.STR.0000169920.64180.fa.
36. Schmitz S.A., O'Regan D.P., Fitzpatrick J., et al. White matter brain lesions in midlife familial hypercholesterolemic patients at 3-Tesla magnetic resonance imaging. Acta Radiol. 2008, 49(2):184-189. 10.1080/02841850701736263.
37. Soljanlahti S., Raininko R., Hyttinen L., et al. Statin-treated familial hypercholesterolemia patients with coronary heart disease and pronounced atherosclerosis do not have more brain lesions than healthy controls in later middle age. Acta Radiol. 2007, 48(8):894-899. 10.1080/02841850701468891.
38. Schmitz S.A., O'Regan D.P., Fitzpatrick J., et al. MRI at 3 Tesla detects no evidence for ischemic brain damage in intensively treated patients with homozygous familial hypercholesterolemia. Neuroradiology 2007, 49(11):927-931. 10.1007/s00234-007-0273-6.
39. Rodriguez G., Bertolini S., Nobili F., et al. Regional cerebral blood flow in familial hypercholesterolemia. Stroke 1994, 25(4):831-836.
40. Postiglione A., Nappi A., Brunetti A., et al. Relative protection from cerebral atherosclerosis of young patients with homozygous familial hypercholesterolemia. Atherosclerosis 1991, 90(1):23-30.
41. Neil A., Cooper J., Betteridge J., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 2008, 29(21):2625-2633. 10.1093/eurheartj/ehn422.
42. Wang W., Zhang B. Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. PLoS One 2014, 9(3):e92388. 10.1371/journal.pone.0092388.
43. Briel M., Studer M., Glass T.R., Bucher H.C. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 2004, 117(8):596-606. 10.1016/j.amjmed.2004.04.022.
44. Heart Protection Study Collaborative G MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(9326):7-22. 10.1016/S0140-6736(02)09327-3.
45. Cholesterol Treatment Trialists C, Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681. 10.1016/S0140-6736(10)61350-5.
46. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015, 372(25):2387-2397. 10.1056/NEJMoa1410489.
47. Kotila M. Declining incidence and mortality of stroke?. Stroke 1984, 15(2):255-259.
48. Broderick J.P., Phillips S.J., Whisnant J.P., O'Fallon W.M., Bergstralh E.J. Incidence rates of stroke in the eighties: the end of the decline in stroke?. Stroke 1989, 20(5):577-582.
49. Struijs J.N., van Genugten M.L., Evers S.M., Ament A.J., Baan C.A., van den Bos G.A. Modeling the future burden of stroke in The Netherlands: impact of aging, smoking, and hypertension. Stroke 2005, 36(8):1648-1655. 10.1161/01.STR.0000173221.37568.d2.